よむ、つかう、まなぶ。
05 参考資料１－２ 13価肺炎球菌コンジュゲートワクチン（成人用）ファクトシート (24 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_36630.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第22回 12／1）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
pneumococcal polysaccharide vaccine on anti-pneumococcal responses following
subsequent pneumococcal vaccination in adults 50 years and older. Vaccine.
31:3594-3602,2013.
35．Goldblatt D, Southern J, Andrews N, Ashton L, Burbidge P, Woodgate S, et al. The
immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent
polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis. 49:1318-1325,
2009.
36．de Roux A, Schmole-Thoma B, Siber GR, Hackell JG, Kuhnke A, Ahlers N, et al. Comparison
of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly
adults: conjugate vaccine elicits improved antibacterial immune responses and
immunological memory. Clin Infect Dis. 46:1015-1023,2008.
37．Miernyk KM, Butler JC, Bulkow LR, Singleton RJ, Hennessy TW, Dentinger CM, et al.
Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate
vaccines in alaska native adults 55-70 years of age. Clin Infect Dis 49:241-248,2009.
38．Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al.
Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl
J Med. 372:1114-1125,2015.
39．厚 生 労 働 省 平 成 23 年 （ 2011 ） 患 者 調 査 の 概 況 http://www.mhlw.go.jp/toukei/
saikin/hw/kanja/11/
40．厚 生 労 働 省 平 成 24 年 （ 2012 ） 医 療 給 付 実 態 調 査
http://www.mhlw.go.jp/stf/
seisakunitsuite/bunya/iryouhoken/database/zenpan/iryoukyufu.html
41．Uematsu H, Kunisawa S, Yamashita K, Imanaka Y. The Impact of Patient Profiles and
Procedures on Hospitalization Costs through Length of Stay in Community-Acquired
Pneumonia Patients Based on a Japanese Administrative Database. PLoS One. 2015 Apr
29;10(4):e0125284.
42．Uematsu H, Kunisawa S, Sasaki N, Ikai H, Imanaka Y. Development of a risk-adjusted
in-hospital mortality prediction model for community-acquired pneumonia: a
retrospective analysis using a Japanese administrative database. BMC Pulm Med. 2014
Dec 16;14:203.
43．Kawakami K, Ohkusa Y, Kuroki R, Tanaka T, Koyama K, Harada Y, et al. Effectiveness
of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the
elderly who receive seasonal influenza vaccine in Japan. Vaccine.28:7063-7069,2010.
44．Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, Hadler S,
Pilishvili T; Centers for Disease Control and Prevention (CDC). Use of 13-valent
pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine
among adults aged ≥65 years: recommendations of the Advisory Committee on
24
subsequent pneumococcal vaccination in adults 50 years and older. Vaccine.
31:3594-3602,2013.
35．Goldblatt D, Southern J, Andrews N, Ashton L, Burbidge P, Woodgate S, et al. The
immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent
polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis. 49:1318-1325,
2009.
36．de Roux A, Schmole-Thoma B, Siber GR, Hackell JG, Kuhnke A, Ahlers N, et al. Comparison
of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly
adults: conjugate vaccine elicits improved antibacterial immune responses and
immunological memory. Clin Infect Dis. 46:1015-1023,2008.
37．Miernyk KM, Butler JC, Bulkow LR, Singleton RJ, Hennessy TW, Dentinger CM, et al.
Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate
vaccines in alaska native adults 55-70 years of age. Clin Infect Dis 49:241-248,2009.
38．Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al.
Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl
J Med. 372:1114-1125,2015.
39．厚 生 労 働 省 平 成 23 年 （ 2011 ） 患 者 調 査 の 概 況 http://www.mhlw.go.jp/toukei/
saikin/hw/kanja/11/
40．厚 生 労 働 省 平 成 24 年 （ 2012 ） 医 療 給 付 実 態 調 査
http://www.mhlw.go.jp/stf/
seisakunitsuite/bunya/iryouhoken/database/zenpan/iryoukyufu.html
41．Uematsu H, Kunisawa S, Yamashita K, Imanaka Y. The Impact of Patient Profiles and
Procedures on Hospitalization Costs through Length of Stay in Community-Acquired
Pneumonia Patients Based on a Japanese Administrative Database. PLoS One. 2015 Apr
29;10(4):e0125284.
42．Uematsu H, Kunisawa S, Sasaki N, Ikai H, Imanaka Y. Development of a risk-adjusted
in-hospital mortality prediction model for community-acquired pneumonia: a
retrospective analysis using a Japanese administrative database. BMC Pulm Med. 2014
Dec 16;14:203.
43．Kawakami K, Ohkusa Y, Kuroki R, Tanaka T, Koyama K, Harada Y, et al. Effectiveness
of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the
elderly who receive seasonal influenza vaccine in Japan. Vaccine.28:7063-7069,2010.
44．Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, Hadler S,
Pilishvili T; Centers for Disease Control and Prevention (CDC). Use of 13-valent
pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine
among adults aged ≥65 years: recommendations of the Advisory Committee on
24